Imbria Pharmaceuticals is a clinical-stage company transforming the treatment of cardiovascular disease by targeting cardiac energy metabolism. The company’s focus is ninerafaxstat, a differentiated, first-in-class cardiovascular therapy. A pipeline-in-a-pill, it has broad potential utility by improving cardiac efficiency without negative effects on heart rate, rhythm, ejection fraction, or blood pressure.

Based in the Boston area, Imbria is backed by a leading syndicate of investors including RA Capital, SV Health Investors, Deep Track Capital, Catalio Capital Management, AN Ventures, and Cytokinetics.